<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583297</url>
  </required_header>
  <id_info>
    <org_study_id>CDX_000001</org_study_id>
    <secondary_id>ABCD</secondary_id>
    <nct_id>NCT00583297</nct_id>
  </id_info>
  <brief_title>Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial</brief_title>
  <acronym>ABCD</acronym>
  <official_title>Identifying Genetic Markers That Predict Microvolt T-wave Alternans Status and Arrhythmia Risk in Patients With Ischemic Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CardioDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CardioDx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ABCD clinical study (ClinicalTrials.gov Identifier NCT00187291) was designed to determine
      if a T-Wave Alternans (TWA) test is equivalent to an Electrophysiology Study (EPS) in
      predicting life-threatening heart rhythms in patients with ischemic heart disease, left
      ventricular dysfunction, and non-sustained tachycardia. The purpose of the ABCD Genetic
      sub-study is to identify genetic markers that predict TWA status and arrhythmia risk in this
      same population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to test the hypothesis that therapy directed primarily
      by a T wave alternans (TWA) test, measured non-invasively during exercise, is equivalent to
      therapy directed by an electrophysiological study (EPS) in predicting spontaneous ventricular
      tachyarrhythmic events (VTEs) in patients with ischemic heart disease, left ventricular
      dysfunction, and asymptomatic non-sustained ventricular tachycardia (NSVT). In the absence of
      any previous life-threatening ventricular arrhythmia (i.e., for primary prevention), ICD
      implantation is currently indicated in patients with ischemic heart disease, left ventricular
      dysfunction, asymptomatic non-sustained ventricular tachycardia, and a positive EPS. The
      objective of this study is to demonstrate that a TWA test directed therapy is equivalent to
      EPS directed therapy in guiding ICD implantation for the purpose of primary prevention of
      sudden cardiac death (SCD) in patients with ischemic heart disease, left ventricular
      dysfunction, and asymptomatic non-sustained ventricular tachycardia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Genotype and Pre-implant T-wave alternans status.</measure>
    <time_frame>two years as per original ABCD trial</time_frame>
    <description>Genotype and Pre-implant T-wave alternans status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotype and occurrence of appropriate cardioversion</measure>
    <time_frame>two years per original ABCD trial</time_frame>
    <description>Genotype and occurrence of appropriate cardioversion for ventricular tachycardia or ventricular fibrillation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">400</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Arrythmia</condition>
  <condition>CVD</condition>
  <arm_group>
    <arm_group_label>ABCD Subjects</arm_group_label>
    <description>The cohort will consist of original subjects of the ABCD trial who consent to participate in the genetic sub-study</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood and saliva.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for the ABCD genetic sub-study includes all living individuals
        currently enrolled in the ABCD trial (total study enrollment=629; 566 analyzed in the
        trial) Participants of the ABCD trial underwent TWA and EPS testing to determine their risk
        for ventricular arrhythmia and most have received an implantable cardioverter defibrillator
        (ICD). The ABCD trial collected extensive longitudinal clinical data including medical and
        medication histories, incidence of ventricular arrhythmias, defibrillator shocks, other
        cardiovascular events, and mortality.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects previously enrolled in the ABCD trial sponsored by St. Jude Medical
        (ClinicalTrials.gov Identifier NCT00187291)

          -  patients with ischemic heart disease

          -  left ventricular ejection fraction (LVEF) &lt; 40%

          -  non-sustained ventricular tachycardia

        Exclusion Criteria:

        Individuals who were not previously enrolled in the ABCD trial are not eligible for this
        genetic sub-study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy J Sehnert, MD</last_name>
    <role>Study Director</role>
    <affiliation>CardioDx, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Kaufman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MetroHealth Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wilson LD, Wan X, Rosenbaum DS. Cellular alternans: a mechanism linking calcium cycling proteins to cardiac arrhythmogenesis. Ann N Y Acad Sci. 2006 Oct;1080:216-34. Review.</citation>
    <PMID>17132786</PMID>
  </reference>
  <reference>
    <citation>Bloomfield DM, Bigger JT, Steinman RC, Namerow PB, Parides MK, Curtis AB, Kaufman ES, Davidenko JM, Shinn TS, Fontaine JM. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol. 2006 Jan 17;47(2):456-63. Epub 2005 Dec 15.</citation>
    <PMID>16412877</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <last_update_submitted>February 21, 2018</last_update_submitted>
  <last_update_submitted_qc>February 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Arrhythmia</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>T-wave Alternans</keyword>
  <keyword>Implanted Cardioverter Defibrillator</keyword>
  <keyword>Biological Markers</keyword>
  <keyword>Molecular Genetics</keyword>
  <keyword>Corus CAD</keyword>
  <keyword>ASGES</keyword>
  <keyword>Age/Sex/Gene Expression Score</keyword>
  <keyword>Gene Expression</keyword>
  <keyword>GES</keyword>
  <keyword>CVD</keyword>
  <keyword>Precision Medicine</keyword>
  <keyword>Sudden Cardiac Death</keyword>
  <keyword>Electrophysiology Study</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>ICD</keyword>
  <keyword>EPS</keyword>
  <keyword>SCD</keyword>
  <keyword>TWA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

